Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Rhea-AI Summary
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease, has announced its participation in the 7th Annual Evercore ISI HealthCONx Conference. The company's management will engage in a fireside chat on Tuesday, December 3, 2024, at 3:00 p.m. ET. Interested parties can access the live webcast through the Investors section of www.acumenpharm.com, where it will remain available for 90 days. The company specializes in developing novel therapeutics targeting toxic soluble amyloid beta oligomers.
Positive
- None.
Negative
- None.
News Market Reaction – ABOS
On the day this news was published, ABOS gained 2.73%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEWTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, Dec. 3, 2024, at 3:00 p.m. ET.
The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.
Investors:
Alex Braun
abraun@acumenpharm.com
Media:
AcumenPR@westwicke.com
FAQ
When is Acumen Pharmaceuticals (ABOS) presenting at the Evercore ISI HealthCONx Conference 2024?
How long will Acumen Pharmaceuticals' (ABOS) HealthCONx Conference webcast be available?
What type of Alzheimer's treatment is Acumen Pharmaceuticals (ABOS) developing?
Where can investors watch Acumen Pharmaceuticals' (ABOS) HealthCONx Conference presentation?
